TOPLINE Among antiretroviral therapy (ART)-naive people with HIV and baseline viral loads ≥ 500,000 copies/mL, more than 90% achieved viral suppression at week 48 with dolutegravir/lamivudine (DTG/3TC). Suppression rates were not significantly different with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF). METHODOLOGY Researchers conducted a retrospective cohort study at a tertiary hospital in Spain to compare the effectiveness of …
Read More
Is DTG/3TC Comparable to Triple Therapy in High Viral Load?
